Cohort study evaluating the efficacy of denosumab to protect against aromatase inhibitor-induced bone loss in Japanese breast cancer patients.
Not Applicable
- Conditions
- Breast Cancer Osteoporosis
- Registration Number
- JPRN-UMIN000014954
- Lead Sponsor
- CYBORG (Chiba Youth Breast Oncology Research Group)
- Brief Summary
The number of registered patient is too small than expected, so we are unable to make a planned analysis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 500
Inclusion Criteria
Not provided
Exclusion Criteria
1. Subject with prior allergy history to therapeutic agents used in this study 2. Evidence of with hypocalcemia 3. Known renal deficiency 4. Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method